Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: A pilot open-label trial

Clinical Neuropharmacology

Volumn 31, Issue 1, 2008, Pages 25-33

  Lerner, Vladimir ^a,e   Miodownik, Chanoch ^a   Gibel, Anatoly ^b   Kovalyonok, Ekateryna ^a   Shleifer, Tatyana ^a   Goodman, Ann B ^c   Ritsner, Michael S ^b,d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e MENTAL HEALTH CENTER   (Israel)

Author keywords

Bexarotene; Negative symptoms; Retinoids; Treatment resistant schizophrenia

Indexed keywords

BEXAROTENE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION; LOW DRUG DOSE; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; THYROID FUNCTION;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SCHIZOPHRENIA; TETRAHYDRONAPHTHALENES;

EID: 40049099691     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31806450da     Document Type: Article

References (44)

1. McCaffery P, Drager DC. High level of a retinoic acid-generating dehydrogenase in the meso telencephalic dopamine system. Proc Natl Acad Sci U S A 1994;91:7772-7776.
2. Nau H, Chahoud I, Dencker L, et al. Teratogenicity of vitamin A and retinoids. In: Blomhoff R, ed. Vitamin A in Health and Disease. Dekker: New York, 1994:615-663.
3. Satre MA, Ugen KE, Kochhar DM. Developmental changes in endogenous retinoids during pregnancy and embryogenesis in the mouse. Biol Reprod 1992; 46:802-810.
4. Wagner E, Luo T, Drager UC. Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb Cortex 2002;12:1244-1253.
5. Arinami T, Gao M, Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577-582.
6. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002;43:1773-1808.
7. Krezel W, Ghyselinck N, Samad TA, et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science;279:863-867.
8. Samad TA, Krezel W, Chambon P, et al. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci U S A 1997;94: 14349-14354.
9. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci U S A 1998;95:7240-7244.
10. Goodman AB. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry 2005;10:620-621.
11. Etchamendy N, Enderlin V, Marighetto A, et al. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res 2003;145: 37-49.
12. Misner DL, Jacobs S, Shimizu Y, et al. Vitamin deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A 2001;98:11714-11719.
13. Alfos S, Boucheron C, Pallet V, et al. A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice. Alcohol Clin Exp Res 2001; 25:1506-1514.
14. Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 2004;20:896-902.
15. Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A 2003; 100:2901-2905.
16. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 2005;75:275-293.
17. Mey J, McCaffery P. Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 2004;10:409-421.
18. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37: 2930-2941.
19. Bischoff ED, Heyman RA, Lamph WW. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 1999;91:2118.
20. Esteva FJ, Glaspy J, Baidas S, et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003;21: 999-1006.
21. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
22. Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 2000;1:514-523.
23. Khuri FR, Rigas JR, Figlin RA, et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:2626-2637.
24. Prince HM, McCormack C, Ryan G, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 2001;42:91-97.
25. Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 2000;6:25-58.
26. Rigas JR, Maurer LH, Meyer LP, et al. Targretin, a selective retinoid X receptor ligand (LGD1069), vinorelbine and cisplatin for the treatment of non small cell lung cancer (NSCLC): a phase I/II trial. Proc Annu Meet Am Soc Clin Oncol 1997: A1724.
27. Shalita AR. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 1987;175(Suppl 1):151-157.
28. MedlinePlus, Health, Information. Drug information: bexarotene (Systemic). 2003. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/ uspdi/500095.html. Accessed July 31, 2003.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
30. White L, Harvey PD, Opler L, et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 1997;30: 263-274.
31. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
32. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233. abstract.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Department of Health, Education and Welfare, 1976.
34. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
35. Hintze JL. User's Guide. NCSS 2000 Statistical System for Windows. Kaysville, Utah: Number Cruncher Statistical Systems, 1998.
36. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1):1-93.
37. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry 2005;18: 175-179.
38. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006;21:369-372.
39. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40:77-97.
40. Njar VC. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Reviews Med Chem 2002;2: 261-269.
41. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005;66:80-84.
42. Palha JA, Goodman AB. Thyroid hormones and retinoids: a possible link between genes and environment in schizophrenia. Brain Res Rev 2006; 51:61-71.
43. Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 2006;209: 598-603.
44. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436: 356-362.